Newly NASDAQ-listed China Nuokang Sees Revenue Growth Spurt
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Underscoring the potential for growth for small biopharmaceutical companies, a Chinese developer and manufacturer of hematological and cardiovascular products reported higher earnings for 2009 and expects growth to carry into 2010